Overview
46,XY difference of sex development (DSD) due to 17-beta-hydroxysteroid dehydrogenase 3 (17β-HSD3) deficiency is a rare autosomal recessive disorder of sex development caused by mutations in the HSD17B3 gene. This enzyme is responsible for converting androstenedione to testosterone in the testes, and its deficiency leads to impaired testosterone biosynthesis during fetal development. The condition is also known as 17-beta-hydroxysteroid dehydrogenase 3 deficiency or 17β-HSD3 deficiency. Affected individuals have a 46,XY karyotype (genetically male) but are typically born with female-appearing or ambiguous external genitalia due to insufficient prenatal virilization. Internal male structures such as the epididymis, vas deferens, and seminal vesicles are usually present because anti-Müllerian hormone production is unaffected, and Müllerian structures (uterus, fallopian tubes) are typically absent. At puberty, significant virilization often occurs due to peripheral conversion of androstenedione to testosterone by other isoenzymes, as well as increased testicular androstenedione production. This can result in deepening of the voice, increased muscle mass, clitoromegaly or phallic growth, and development of a more masculine body habitus. Gynecomastia may also occur. Many individuals raised as female experience gender role changes at puberty. The testes may be located in the inguinal canal or labioscrotal folds, and there is an increased risk of gonadal tumors if the testes remain undescended. Management depends on the gender of rearing and individual circumstances. For individuals raised female, treatment may include gonadectomy (to prevent virilization at puberty and reduce tumor risk) followed by estrogen replacement therapy. For those raised male or who transition to a male gender role, testosterone supplementation and surgical correction of the genitalia may be offered. Psychological support and multidisciplinary care involving endocrinologists, urologists, psychologists, and geneticists are essential components of management. The condition is particularly prevalent in certain populations, including the Gaza Strip and parts of the Dominican Republic, where consanguinity rates are higher.
Also known as:
Clinical phenotype terms— hover any for plain English:
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for 46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for 46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for 46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to 46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency.
Community
No community posts yet. Be the first to share your experience with 46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency.
Start the conversation →Latest news about 46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency
No recent news articles for 46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about 46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency
What is 46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency?
46,XY difference of sex development (DSD) due to 17-beta-hydroxysteroid dehydrogenase 3 (17β-HSD3) deficiency is a rare autosomal recessive disorder of sex development caused by mutations in the HSD17B3 gene. This enzyme is responsible for converting androstenedione to testosterone in the testes, and its deficiency leads to impaired testosterone biosynthesis during fetal development. The condition is also known as 17-beta-hydroxysteroid dehydrogenase 3 deficiency or 17β-HSD3 deficiency. Affected individuals have a 46,XY karyotype (genetically male) but are typically born with female-appearing
How is 46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency inherited?
46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does 46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency typically begin?
Typical onset of 46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency is neonatal. Age of onset can vary across affected individuals.